Error loading player: No playable sources found

127305

CASSS Welcome & CGTP Fall Virtual Summit 2024 Introduction

Date
November 19, 2024
This product is not available for individual purchase, but it is available as part of the following products:

Summit Chair: JR Dobbins, Eli Lilly and Company


Accelerating the Development of Adeno-Associated Viral Vector Gene Therapies: Innovations in Chemistry, Manufacturing, and Control 


Gene therapy using adeno-associated viral (AAV) vectors has emerged as a transformative approach for treating a variety of genetic conditions. Many of these novel therapies are being developed to treat rare diseases with unmet medical needs, necessitating the rapid advancement through development and commercialization. The inherent complexity of AAV vectors has historically presented challenges in advancing the chemistry, manufacturing, and control (CMC) aspects commensurate with the pace of clinical development.


This virtual summit will bring individuals from academia, industry, and health authorities together to discuss innovative CMC approaches. Attendees will gain insights into CMC strategies, challenges, and opportunities to accelerate the development and commercialization of AAV therapies. The summit will be comprised of two sessions that focus on development of the process and product control strategy along with commercialization topics such as technology transfer and process performance qualification strategies. Each session will consist of multiple presentations and a panel discussion providing attendees the opportunity to learn from and interact with experts in the field.  


By attending this summit, you will connect virtually with a relevant global network and gain tangible knowledge to help you more rapidly and robustly advance these transformative AAV vector therapies to patients who need them. 

Session Chair


Related Products

Thumbnail for Session II - Development and Manufacturing Strategies Enabling the Commercialization of AAV Therapies & Session II: Panel Discussion - Questions & Answers
Session II - Development and Manufacturing Strategies Enabling the Commercialization of AAV Therapies & Session II: Panel Discussion - Questions & Answers
Session Chairs: JR Dobbins, _Eli Lilly and Company_, Darius Pillsbury, _ValSource Inc_., and Jennifer Wellman, _Akouos, Inc…
Thumbnail for Session I - Mastering the Art of Control: CQAs and Considerations for Control Strategies for AAV-based Therapeutics & Session I - Panel Discussion - Questions & Answers
Session I - Mastering the Art of Control: CQAs and Considerations for Control Strategies for AAV-based Therapeutics & Session I - Panel Discussion - Questions & Answers
CQAs are essential attributes that must be monitored and controlled to ensure product quality. Understanding and defining CQAs has been challenging in the relatively new field of gene therapy, but is crucial to ensure patient safety and to meet regulatory standards…
Thumbnail for CGTP Fall Virtual Summit 2024 Closing Remarks
CGTP Fall Virtual Summit 2024 Closing Remarks
Summit Chair: JR Dobbins, Eli Lilly and Company